PMN
Price
$0.50
Change
-$0.00 (-0.00%)
Updated
May 22, 02:48 PM (EDT)
Capitalization
16.22M
88 days until earnings call
SYRE
Price
$15.11
Change
+$0.33 (+2.23%)
Updated
May 22, 04:59 PM (EDT)
Capitalization
892.03M
70 days until earnings call
Interact to see
Advertisement

PMN vs SYRE

Header iconPMN vs SYRE Comparison
Open Charts PMN vs SYREBanner chart's image
ProMIS Neurosciences
Price$0.50
Change-$0.00 (-0.00%)
Volume$5.84K
Capitalization16.22M
Spyre Therapeutics
Price$15.11
Change+$0.33 (+2.23%)
Volume$8.99K
Capitalization892.03M
PMN vs SYRE Comparison Chart
Loading...
PMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PMN vs. SYRE commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PMN is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (PMN: $0.50 vs. SYRE: $14.78)
Brand notoriety: PMN and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PMN: 42% vs. SYRE: 40%
Market capitalization -- PMN: $16.22M vs. SYRE: $892.03M
PMN [@Biotechnology] is valued at $16.22M. SYRE’s [@Biotechnology] market capitalization is $892.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.18B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PMN’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • PMN’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, SYRE is a better buy in the long-term than PMN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PMN’s TA Score shows that 3 TA indicator(s) are bullish while SYRE’s TA Score has 3 bullish TA indicator(s).

  • PMN’s TA Score: 3 bullish, 4 bearish.
  • SYRE’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, PMN is a better buy in the short-term than SYRE.

Price Growth

PMN (@Biotechnology) experienced а -1.72% price change this week, while SYRE (@Biotechnology) price change was -0.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.82%. For the same industry, the average monthly price growth was +7.45%, and the average quarterly price growth was -1.67%.

Reported Earning Dates

PMN is expected to report earnings on Aug 18, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.82% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($892M) has a higher market cap than PMN($16.2M). PMN has higher P/E ratio than SYRE: PMN (5.51) vs SYRE (1.72). SYRE YTD gains are higher at: -36.512 vs. PMN (-47.637). PMN has higher annual earnings (EBITDA): -391.76K vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. PMN (21.6M). SYRE has less debt than PMN: SYRE (0) vs PMN (4.05M). PMN (0) and SYRE (0) have equivalent revenues.
PMNSYREPMN / SYRE
Capitalization16.2M892M2%
EBITDA-391.76K-214.36M0%
Gain YTD-47.637-36.512130%
P/E Ratio5.511.72321%
Revenue00-
Total Cash21.6M565M4%
Total Debt4.05M0-
FUNDAMENTALS RATINGS
PMN vs SYRE: Fundamental Ratings
PMN
SYRE
OUTLOOK RATING
1..100
5716
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9364
P/E GROWTH RATING
1..100
9980
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYRE's Valuation (75) in the Pharmaceuticals Major industry is in the same range as PMN (94) in the null industry. This means that SYRE’s stock grew similarly to PMN’s over the last 12 months.

SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PMN (100) in the null industry. This means that SYRE’s stock grew similarly to PMN’s over the last 12 months.

SYRE's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as PMN (100) in the null industry. This means that SYRE’s stock grew similarly to PMN’s over the last 12 months.

SYRE's Price Growth Rating (64) in the Pharmaceuticals Major industry is in the same range as PMN (93) in the null industry. This means that SYRE’s stock grew similarly to PMN’s over the last 12 months.

SYRE's P/E Growth Rating (80) in the Pharmaceuticals Major industry is in the same range as PMN (99) in the null industry. This means that SYRE’s stock grew similarly to PMN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PMNSYRE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 22 days ago
82%
Bullish Trend 11 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 7 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HUSA0.670.04
+5.61%
Houston American Energy Corp
WPM85.272.29
+2.76%
Wheaton Precious Metals Corp
ZLAB32.59-0.04
-0.12%
Zai Lab Limited
COFS29.74-0.75
-2.46%
ChoiceOne Financial Services
QTRX4.81-0.18
-3.61%
Quanterix Corp

PMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PMN has been loosely correlated with SYRE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PMN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMN
1D Price
Change %
PMN100%
-5.47%
SYRE - PMN
44%
Loosely correlated
-4.03%
BBIO - PMN
42%
Loosely correlated
-2.58%
ABOS - PMN
33%
Poorly correlated
-1.89%
LIXT - PMN
27%
Poorly correlated
+2.48%
NBY - PMN
26%
Poorly correlated
-5.08%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with BEAM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-4.03%
BEAM - SYRE
58%
Loosely correlated
-2.99%
APGE - SYRE
53%
Loosely correlated
-0.40%
ACLX - SYRE
52%
Loosely correlated
+8.26%
KYMR - SYRE
52%
Loosely correlated
-4.17%
CGON - SYRE
52%
Loosely correlated
-1.28%
More